More MS news articles for Jan 2002

Nabilone Reduces Levodopa-Induced Dyskinesia in Parkinson's Disease

NEW YORK (Reuters Health) Dec 28 - Nabilone, a cannabinoid receptor agonist, reduces gamma-aminobutyric acid (GABA) reuptake in the globus pallidus (GPI) and reduces levodopa-induced dyskinesia in Parkinson's disease (PD), according to a report in the December 11th issue of Neurology.

Dr. J. M. Brotchie, of the University of Manchester, UK, and colleagues recruited nine patients with a clinical diagnosis of idiopathic PD who experienced stable levodopa-induced dyskinesia for 25% to 50% of the day, to examine the effects of nabilone in a double-blind, randomized, placebo-controlled, crossover fashion. Seven subjects completed the study.

Two levodopa challenges were performed 2 weeks apart. "All antiparkinsonian medication was omitted from 9 PM the night before the study," the team explains. They administered nabilone or placebo in two split doses 12 hours and 1 hour before administration of levodopa and made assessments after the second dose of nabilone/placebo.

"Nabilone significantly reduced total levodopa-induced dyskinesia compared with placebo," the authors report. The median total dyskinesia score after treatment with levodopa and nabilone was 17, compared with 22 after treatment with levodopa and placebo (p < 0.05).

Compared with placebo, the mean percentage reduction in total on-period dyskinesia after nabilone treatment was 22%. The team observed no difference in the duration of the on period, and there was no effect on the antiparkinsonian action of levodopa with nabilone administration.

Neurology 2001;57:2108-2111.

Copyright © 2001 Reuters Ltd